MX347454B - Anticuerpos monoclonales inhibidores anti-factor xii-xiia. - Google Patents

Anticuerpos monoclonales inhibidores anti-factor xii-xiia.

Info

Publication number
MX347454B
MX347454B MX2014000363A MX2014000363A MX347454B MX 347454 B MX347454 B MX 347454B MX 2014000363 A MX2014000363 A MX 2014000363A MX 2014000363 A MX2014000363 A MX 2014000363A MX 347454 B MX347454 B MX 347454B
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
factor xii
inhibitory anti
xiia
xiia monoclonal
Prior art date
Application number
MX2014000363A
Other languages
English (en)
Other versions
MX2014000363A (es
Inventor
Nolte Marc
Panousis Con
Rayzman Veronika
Nash Andrew
Wilson Michael
Schmidbauer Stefan
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11175105A external-priority patent/EP2548892A1/en
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2014000363A publication Critical patent/MX2014000363A/es
Publication of MX347454B publication Critical patent/MX347454B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a anticuerpos inhibitorios anti-factor XII/FXIIa y métodos para su uso.
MX2014000363A 2011-07-22 2012-07-20 Anticuerpos monoclonales inhibidores anti-factor xii-xiia. MX347454B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510801P 2011-07-22 2011-07-22
EP11175105A EP2548892A1 (en) 2011-07-22 2011-07-22 Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
EP12153310 2012-01-31
PCT/EP2012/064322 WO2013014092A1 (en) 2011-07-22 2012-07-20 Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses

Publications (2)

Publication Number Publication Date
MX2014000363A MX2014000363A (es) 2014-03-27
MX347454B true MX347454B (es) 2017-04-27

Family

ID=47600530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000363A MX347454B (es) 2011-07-22 2012-07-20 Anticuerpos monoclonales inhibidores anti-factor xii-xiia.

Country Status (26)

Country Link
US (5) US9518127B2 (es)
EP (2) EP4516811A3 (es)
JP (1) JP6253578B2 (es)
KR (1) KR102042982B1 (es)
CN (1) CN103687878B (es)
AU (1) AU2012289001B2 (es)
BR (1) BR112014001104B1 (es)
CA (1) CA2841185C (es)
DK (1) DK2734552T3 (es)
ES (1) ES3005912T3 (es)
FI (2) FI2734552T3 (es)
FR (1) FR25C1026I1 (es)
HR (1) HRP20250164T1 (es)
HU (2) HUE070002T2 (es)
IL (2) IL230564B2 (es)
LT (2) LT2734552T (es)
MX (1) MX347454B (es)
NL (1) NL301332I2 (es)
NO (1) NO2025031I1 (es)
PL (1) PL2734552T3 (es)
PT (1) PT2734552T (es)
RS (1) RS66465B1 (es)
RU (1) RU2660370C2 (es)
SI (1) SI2734552T1 (es)
SM (1) SMT202500041T1 (es)
WO (1) WO2013014092A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2734552T3 (fi) * 2011-07-22 2025-02-12 Csl Behring Gmbh Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
US20160166660A1 (en) * 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
BR112016029624A2 (pt) 2014-06-18 2017-10-24 Csl Behring Gmbh terapia usando um inibidor do fator xii em um distúrbio neurotraumático
IL253180B2 (en) * 2015-01-02 2023-04-01 Dyax Corp Bispecific antibodies against plasma kallikrein and factor xii
KR102794955B1 (ko) * 2015-07-21 2025-04-15 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
BR112018014810A2 (pt) * 2016-01-22 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-fator xi de coagulação
KR20230136687A (ko) 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
CN111479587B (zh) * 2017-12-15 2024-01-09 杰特有限公司 FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用
MA52966A (fr) * 2018-06-19 2021-04-28 Regeneron Pharma Anticorps anti-facteur xii/xiia et leurs utilisations
JP7478149B2 (ja) * 2018-11-28 2024-05-02 オレゴン ヘルス アンド サイエンス ユニバーシティー 治療用第ｘｉｉ因子抗体
CN114072425A (zh) * 2019-06-12 2022-02-18 杰特创新股份有限公司 可溶性补体受体1型变体缀合物及其用途
US20230002508A1 (en) * 2019-12-03 2023-01-05 CSL Innovation Pty Ltd Use of an anti-factor xii antibody for the treatment or prevention of hereditary angioedema
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
BR112022026482A2 (pt) * 2020-07-03 2023-01-31 CSL Innovation Pty Ltd Formulação altamente concentrada de proteínas de ligação ao antígeno do fator xii
CN116265945B (zh) * 2022-01-05 2025-12-09 上海迈晋生物医药科技有限公司 抗凝血药物的生物学活性检测方法
CN121358781A (zh) 2023-06-16 2026-01-16 江苏贝捷泰生物科技有限公司 特异性识别因子XIIa的抗体及其应用
CN121568964A (zh) 2023-07-19 2026-02-24 里珍纳龙药品有限公司 抗因子XII/XIIa抗体及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) * 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DE69233069T2 (de) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20040077538A1 (en) 2000-05-17 2004-04-22 Harvey Pollard Use of factor XIIa for treatment of hemophilia A and B and prevention of bleeding
DE60143798D1 (de) * 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
JP2006505291A (ja) * 2002-11-08 2006-02-16 ヘマテック，エルエルシー プリオンタンパク質活性が低減されたトランスジェニック有蹄動物及びその用途
EP1573339A2 (en) * 2002-12-20 2005-09-14 Axis-Shield Diagnostics Limited Detection or determination of variants of factor xiia
GB0229837D0 (en) * 2002-12-20 2003-01-29 Axis Shield Diagnostics Ltd Variants of activated factor XII
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
JP2007528721A (ja) * 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
WO2005024044A2 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
AU2005271523B2 (en) * 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
WO2006033386A1 (ja) 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
JP5118492B2 (ja) * 2004-12-23 2013-01-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血栓の形成の防止および／または安定化の防止
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
NZ576195A (en) 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
ES2753183T3 (es) 2007-02-12 2020-04-07 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
US8114968B2 (en) * 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
MX2011005481A (es) * 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
RS62853B1 (sr) * 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AU2012204202A1 (en) * 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
FI2734552T3 (fi) * 2011-07-22 2025-02-12 Csl Behring Gmbh Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö

Also Published As

Publication number Publication date
KR102042982B1 (ko) 2019-11-11
US20140199361A1 (en) 2014-07-17
IL291613A (en) 2022-05-01
IL291613B1 (en) 2025-08-01
RU2660370C2 (ru) 2018-07-05
AU2012289001B2 (en) 2016-03-03
HUS2500028I1 (hu) 2025-07-28
LT2734552T (lt) 2025-01-10
FI2734552T3 (fi) 2025-02-12
CN103687878B (zh) 2018-01-09
FR25C1026I1 (fr) 2025-09-19
CA2841185A1 (en) 2013-01-31
ES3005912T3 (en) 2025-03-17
US20200062863A1 (en) 2020-02-27
EP2734552B1 (en) 2024-11-13
JP2014523253A (ja) 2014-09-11
SI2734552T1 (sl) 2025-03-31
IL230564B2 (en) 2023-09-01
NL301332I2 (nl) 2025-09-10
HK1198334A1 (en) 2015-04-02
BR112014001104B1 (pt) 2022-12-06
FIC20250024I1 (fi) 2025-07-08
EP4516811A3 (en) 2025-03-26
JP6253578B2 (ja) 2017-12-27
SMT202500041T1 (it) 2025-03-12
IL291613B2 (en) 2025-12-01
HUE070002T2 (hu) 2025-04-28
BR112014001104A2 (pt) 2017-12-12
EP4516811A2 (en) 2025-03-05
KR20140054112A (ko) 2014-05-08
US20170121423A1 (en) 2017-05-04
US9856325B2 (en) 2018-01-02
IL230564A0 (en) 2014-03-31
PL2734552T3 (pl) 2025-03-24
HRP20250164T1 (hr) 2025-04-11
MX2014000363A (es) 2014-03-27
AU2012289001A1 (en) 2013-05-02
IL230564B1 (en) 2023-05-01
CN103687878A (zh) 2014-03-26
DK2734552T3 (da) 2024-12-09
US11345759B2 (en) 2022-05-31
US20170137536A1 (en) 2017-05-18
RU2014106652A (ru) 2015-08-27
EP2734552A1 (en) 2014-05-28
LTPA2025524I1 (es) 2025-07-10
US9856326B2 (en) 2018-01-02
WO2013014092A1 (en) 2013-01-31
CA2841185C (en) 2021-05-25
NZ619385A (en) 2016-07-29
NO2025031I1 (no) 2025-07-09
US10513560B2 (en) 2019-12-24
US20180134806A1 (en) 2018-05-17
US9518127B2 (en) 2016-12-13
RS66465B1 (sr) 2025-02-28
PT2734552T (pt) 2025-01-29

Similar Documents

Publication Publication Date Title
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX2018010572A (es) Inmunoglobulinas heterodimericas.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2022000026A (es) Anticuerpos para tau.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
EA201391248A1 (ru) Биспецифические связывающие агенты
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
WO2012166659A3 (en) Anti-emr1 antibodies
EA201291316A1 (ru) Чистка установок hf-алкилирования
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
UA72478U (ru) Применение полентара как средства фригопротекторного действия

Legal Events

Date Code Title Description
FG Grant or registration